Nicole Longo Nicole is senior director of public affairs at PhRMA focusing on Medicare, 340B, importation and more. She previously worked for a D.C.-based public affairs firm where she assisted a wide range of clients with communications efforts on everything from trade policy to agriculture policy to health care policy. Outside the office, Nicole can be found trying new restaurants (usually Italian), taking an occasional barre class and cheering on the Cincinnati Bengals.
Recent Posts
Proposed change to Medicaid line extension definition ignores importance of critical improvements in treatments
By Nicole Longo | October 13, 2020
In comments recently submitted to the administration, PhRMA raised concerns with a number of changes included in the Centers for Medicare & Medicaid Services (CMS) Medicaid proposed rule. Today,...
Read More
Growth in 340B program has not translated to improvements for patients
By Nicole Longo | October 5, 2020
Is 340B benefiting the vulnerable, uninsured patients it was designed to help? That’s the most important question policymakers should be asking in any discussion about the 340B program....
Read More
Recent administration actions undermine patient assistance programs
By Nicole Longo | September 16, 2020
While all eyes and ears are focused on COVID-19 and beating this pandemic, the administration has pursued harmful policy changes that we can’t let slip under the radar. In two back-to-back...
Read More
Executive order threatens R&D when we need it most to fight COVID-19
By Nicole Longo | July 30, 2020
In case you missed it, President Trump recently signed executive orders that would implement sweeping changes to the biopharmaceutical industry. While his intention may have been to help Americans...
Read More
PhRMA submits comments to CMS on Medicaid proposed rule
By Nicole Longo | July 21, 2020
In response to the Centers for Medicare and Medicaid Services’ (CMS) proposed rule regarding changes to Medicaid, PhRMA provided feedback on how the changes included would have widespread impacts...
Read More
By the numbers: A look at the sourcing of API used in medicines consumed in the United States
By Nicole Longo | July 16, 2020
There has been a lot of focus of late on where active pharmaceutical ingredients (APIs) for medicines are manufactured. While some may claim we are reliant on other countries, putting us at risk...
Read More
Stakeholders raise concerns with proposed drastic changes to the pharmaceutical supply chain
By Nicole Longo | June 11, 2020
As we work to combat the current global pandemic, it is especially critical to maintain the stability of our global manufacturing supply chain. Unfortunately, recent policy proposals that would...
Read More
America’s global leadership in biopharmaceutical manufacturing
By Nicole Longo | June 4, 2020
Unfortunately, there are a lot of assertions floating around that tell a misleading story about pharmaceutical manufacturing, diminishing America’s leadership and suggesting our reliance on other...
Read More
It’s a good thing pharmaceutical manufacturing supply chains are spread out around the world
By Nicole Longo | May 21, 2020
The biopharmaceutical industry is committed to ensuring Americans and people around the world have access to the medicines they need. As a result, companies do everything they can to make sure...
Read More
Setting up a pharmaceutical manufacturing supply chain is a complex and lengthy process
By Nicole Longo | May 14, 2020
Did you know that biopharmaceutical manufacturers must begin setting up the manufacturing supply chain for a medicine years before that medicine is even approved for use by patients? That’s a fact...
Read More
Medicare Monday (100)
340B Spotlight (46)
Cost & Consequence (0)
